Holen Sie sich die Stockscreener-App
1.7142
0.91%
-0.0158
Schlusskurs vom Vortag:
$1.73
Offen:
$1.7169
24-Stunden-Volumen:
4,445
Relative Volume:
0.02
Marktkapitalisierung:
$3.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.77M
KGV:
-0.6477
EPS:
-2.6464
Netto-Cashflow:
$-2.69M
1W Leistung:
+1.43%
1M Leistung:
-30.88%
6M Leistung:
-20.18%
1J Leistung:
-57.97%
1-Tages-Spanne:
$1.70
$1.7946
1-Wochen-Bereich:
$1.69
$1.7946
52-Wochen-Spanne:
$1.5901
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Firmenname
Xortx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare XRTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
1.7142 | 3.07M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten
XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis - kalkine.ca
XORTX Therapeutics (XRTX) Edges Lower to $1.70, Holding Just Above Near-Term SupportWeekly Profile - siam.in
Price to sales forward of XORTX Therapeutics, Inc. – HAN:ANU - TradingView
XRTX Forecast — Price Target — Prediction for 2027 - TradingView
Why XORTX Therapeutics Inc. (NASDAQ:XRTX) Is In Focus Now? - kalkinemedia.com
XRTX Jumps As XORTX Advances XORLO Gout Program Plans - timothysykes.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
XORTX plans FDA IND filing for XRx-026 gout program - grafa.com
XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing - StocksToTrade
XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Therapy - TipRanks
A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan - Stock Titan
XORTX Therapeutics Plans Q4 2026 FDA IND Submission for XRx-026 Gout Program Using XORLO™, Eyes US$700M Market - kalkine.ca
Vectus Biosystems Releases FY2026 Annual Report, Details CEO Appointment and VB0004 Development - kalkine.com.au
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XORTX (XRTX) Stock Analysis: -6.74% Down — Bearish Signals to Watch 2026-09-17OBV Breakout - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Shares Rise 16.11% After HoursXORTX Therapeutics (NASDAQ:XRTX) - Benzinga
XORTX Therapeutics Initiates GMP Manufacturing of XORLO™ to Advance Gout Treatment Clinical Trials - Kalkine Media
Xortx Therapeutics Inc Announces the Launch of Production of Drug Material and Tablet Manufacturing - marketscreener.com
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program - TipRanks
XORTX Therapeutics (XRTX) begins making new gout drug - Stock Titan
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - The Manila Times
XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist - Stock Titan
Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
Price to earnings forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
EBITDA margin % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView
Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages Investor Relations Program - markets.businessinsider.com
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - TipRanks
XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView
XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - kalkinemedia.com
Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView
Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView
Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - ad-hoc-news.de
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Announces Termination and Postponement of Investor Relations Program - marketscreener.com
XORTX Therapeutics Inc. (XRTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
XORTX Therapeutics Inc. (XRTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - Stock Titan
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Finanzdaten der Xortx Therapeutics Inc-Aktie (XRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):